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The NK cell–activating receptor NKG2D interacts with three different cellular ligands, all of 
which are regulated by mouse cytomegalovirus (MCMV). We set out to define the viral gene 
product regulating murine UL16-binding protein-like transcript (MULT)-1, a newly 
described NKG2D ligand. We show that MCMV infection strongly induces MULT-1 gene 
expression, but surface expression of this glycoprotein is nevertheless completely abolished 
by the virus. Screening a panel of MCMV deletion mutants defined the gene 
 
m145
 
 as the 
viral regulator of MULT-1. The MCMV 
 
m145-
 
encoded glycoprotein turned out to be 
necessary and sufficient to regulate MULT-1 by preventing plasma membrane residence of 
MULT-1. The importance of MULT-1 in NK cell regulation in vivo was confirmed by the 
attenuating effect of the 
 
m145
 
 deletion that was lifted after NK cell depletion. Our 
findings underline the significance of escaping MULT-1/NKG2D signaling for viral survival 
and maintenance.
 
Mouse CMV (MCMV) shares many features
with human CMV (HCMV) and serves as a
model to study the immunobiology of CMV
infections. Both innate and acquired immunity
are important for host control of CMV (1, 2).
In spite of this, CMV can establish life-long
persistence characterized by alternate stages of
latency and low-level virus productivity (3). It
is generally assumed that viral proteins that
counteract the host immune system are essential
to tune the virus–host balance. For example, to
escape CD8
 
 
 
 CTL control, three MCMV
proteins efficiently down-regulate MHC class
I expression (4). However, the altered MHC
class I expression should predispose infected
cells to lysis by NK cells, as suggested by the
“missing self” hypothesis (5). In contrast, most
laboratory mouse strains, as well as wild mice,
fail to generate a significant NK cell response
to MCMV (6), with the exception of strains in
which the MCMV 
 
m157
 
-encoded protein leads
to NK cell activation (7–9).
The NKG2D receptor binds ligands that
are poorly expressed on normal cells, but are
up-regulated on infected, transformed, or stressed
cells (10). These ligands are distantly related
to MHC class I molecules. Known mouse
NKG2D ligands comprised the retinoic acid
early inducible (RAE)-1 family of proteins (11),
the minor histocompatibility antigen H60 (12,
13), and the murine UL16-binding protein-
like transcript (MULT)-1 glycoprotein (14,
15). NKG2D receptor triggering can override
signals by MHC class I–specific inhibitory NK
cell receptors (16, 17). This suggests, along
with the fact that NKG2D is expressed on CD8
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T cells and 
 
  
 
 T cells, a pivotal position of NKG2D in both
innate and adaptive immunity (18).
We have set out to define the viral modulators of
NKG2D ligands. MCMV 
 
m152
 
/gp40 has a double role and
not only modulates the plasma membrane expression of
MHC class I molecules but also of NKG2D ligands, namely
RAE-1 (19–21). The protein encoded by MCMV 
 
m155
 
modulates the H60 ligand (22, 23). Considering the fact that
MCMV-infected cells show a complete absence of all
NKG2D ligands on the plasma membrane, we concluded
that MCMV genes must also be involved in the down-regu-
lation of MULT-1. Here, we identify the responsible MCMV
gene 
 
m145
 
 and describe its effect upon MULT-1 expression
and its role during NK cell defense in vivo.
 
RESULTS
Members of the MCMV 
 
m145
 
 gene family down-modulate 
NKG2D ligands
 
MCMV encodes proteins responsible for the down-regula-
tion of all mouse NKG2D ligands (19). The 
 
m152
 
 gene, re-
Figure 1. NKG2D ligands are down-regulated by protein products of 
MCMV genes located between m144-m158. (A) The HindIII cleavage 
map of the MCMV genome is shown (top) and the expanded region below 
indicates the positions of the m145 gene family members (shaded boxes) 
in the WT (w.t.) virus as well as the deletions (dashed lines) of the recombi-
nant viruses. (B) NIH/3T3 cells were analyzed for expression of surface 
NKG2D ligands by staining with PE-NKG2D tetramer upon 12-h infection 
with indicated GFP-expressing viruses. Cells stained with streptavidin-PE 
were used as negative controls (dotted line). (C) NIH/3T3 and B12 cells 
were infected with indicated viruses and, after 12 h, stained with anti-H60 
and anti–RAE-1 , ,  mAbs, respectively. Cells stained with second antibody 
only were used as negative control (dotted line). (B and C) Each histogram 
represents 104 gated propidium iodide-negative, GFP-positive (infected) or 
GFP-negative (uninfected) cells. 
JEM VOL. 201, January 17, 2005
 
213
 
ARTICLE
 
sponsible for the down-modulation of RAE-1 (20) and sev-
eral other MCMV genes involved in the regulation of NK
cell response, belongs to the 
 
m145
 
 gene family (24), which
shares properties with MHC class I proteins (7). Therefore,
we postulated that other members of this gene family might
be involved in the modulation of the expression of NKG2D
ligands. To this aim, we assessed the expression of NKG2D
ligands upon infection with several MCMV deletion mutants
lacking genes of the 
 
m145
 
 gene family (Fig. 1, A and B).
NIH/3T3 cells were stained with NKG2D tetramer 12 h af-
ter infection with the deletion mutant 
 
 
 
6 (
 
 
 
m144
 
–
 
m158
 
) and
three additional mutants that dissect the genes deleted in 
 
 
 
6
into three subgroups: 
 
 
 
6S1 (
 
 
 
m144
 
–
 
m148
 
), 
 
 
 
6S2 (
 
 
 
m149
 
–
 
m153
 
), and 
 
 
 
6S3 (
 
 
 
m154
 
–
 
m157
 
). All the mutants, including
the virus here referred to as WT MCMV, were constructed
to express also GFP (25), to permit the selective analysis of in-
fected cells. Cells infected with WT MCMV lost membrane
staining with NKG2D tetramer. The same was observed
upon infection with a WT virus that does not express GFP
(unpublished data). In contrast, cells infected with the dele-
tion mutant 
 
 
 
6 displayed an expression level of NKG2D
ligands on the cell surface comparable to that of uninfected
control. The gene 
 
m152
 
 is deleted in 
 
 
 
6, and reexpression of
RAE-1 should contribute to restoration of NKG2D ligands
after infection with this mutant. Therefore, we tested the ef-
fect of mutants that lack subsets of genes of the m145 family.
The 
 
 
 
6S2 mutant also lacks 
 
m152
 
 and revealed that the dele-
tion of this genetic region only partially restores the NKG2D
ligand expression. A similar phenotype was exhibited by mu-
tant 
 
 
 
6S3 in which the H60 regulator 
 
m155
 
 is deleted (22).
Because the mutant 
 
 
 
6S1 also partially lifted NKG2D expres-
sion, we expected another unknown regulator in this genetic
region. The staining with anti–RAE-1
 
 
 
,
 
 
 
,
 
 
 
 and anti-H60
mAbs upon infection with 
 
 
 
6S1 and single gene deletion
mutant viruses lacking defined open reading frames (ORFs)
from the genomic region 
 
m144–m148
 
 revealed down-regula-
tion of RAE-1 and H60 to an extent identical with WT
MCMV-infected cells (Fig. 1 C). We concluded that the tar-
get for the gene situated within this region must be a different
NKG2D ligand, most likely MULT-1.
 
Characterization of an anti–MULT-1 mAb and selection of 
MULT-1–expressing cell lines
 
To focus on MULT-1, we generated a rat monoclonal anti-
body against the MULT-1 glycoprotein. The specificity of
resulting antibodies was confirmed by the staining of cells in-
fected with the recombinant vaccinia virus expressing HA-
tagged MULT-1 protein (MULT-1-VV). As shown in Fig.
2 A, CV-1 cells infected with MULT-1-VV showed a bright
staining with anti–MULT-1 mAb, whereas cells infected
with WT VV were negative. Staining of BALB/3T3 cells
with mAbs against H60, RAE-1, and MULT-1 clearly dem-
onstrated that these cells constitutively express H60 and
RAE-1 but not MULT-1 on their surface, and ruled out the
possibility that anti–MULT-1 mAb cross-reacts with any of
the other two NKG2D ligands (Fig. 2 B). In addition, im-
munoprecipitation of lysates of metabolically labeled cells,
stably transfected with HA-tagged MULT-1 (MULT-1-
3T3) using anti–MULT-1 antibody coupled to protein
G–Sepharose, revealed the presence of an 
 
 
 
53-kD band that
shifts to a 43-kD–sized band upon EndoH digestion (Fig. 2
C). A band of the same size was seen upon immunoprecipi-
tation with anti-HA mAb, confirming the specificity of the
anti–MULT-1 antibody (unpublished data).
Several cell lines that constitutively express MULT-1:
SVEC4-10, B12, NIH/3T3, TpnT, IC21, and M2-10B4
were screened. Because SVEC4-10 cells expressed MULT-1
but neither RAE-1
 
 
 
,
 
 
 
,
 
 
 
 nor H60 (unpublished data), these
cells were used to narrow down the MCMV gene region in-
volved in the regulation of MULT-1.
 
The 
 
m145
 
 gene product modulates cell membrane 
expression of MULT-1 protein
 
To assess which MCMV protein affects the surface expres-
sion of MULT-1, SVEC4-10 cells were infected with WT
MCMV or specific deletion mutants and stained with the
anti–MULT-1 mAb 12 h after infection. As suggested in
Fig. 1 B and shown in Fig. 3 A, the 
 
 
 
6 mutant lacked the
MULT-1 down-regulating function, whereas the 
 
 
 
6S2 or
 
 
 
6S3 mutants still maintained it. Cells infected with the
 
 
 
6S1 mutant lacking genes 
 
m144
 
–
 
m148
 
 preserved the mem-
brane expression of MULT-1 at a level comparable to or
even higher than that of uninfected cells, pointing to five
candidate genes that may be responsible for the down-regu-
lation of surface expressed MULT-1. A panel of single dele-
tion mutant viruses was tested that where lacking individual
genes within the genomic region deleted in 
 
 
 
6S1. Only the
 
 
 
m145
 
 mutant turned out to be unable to down-regulate
Figure 2. Testing of anti–MULT-1 mAb. (A) CV-1 cells were infected 
with three MOI of WT VV or MULT-1-VV per cell and stained with anti–
MULT-1 mAb 14 h after infection. (B) BALB/3T3 cells were stained with 
PE-NKG2D tetramer, anti–RAE-1 , ,  or anti–MULT-1 antibodies. 
(A and B) Cells incubated with second antibody were used as a negative 
control (dotted line). Each histogram represents 104 gated propidium 
iodide–negative cells. (C) Upon metabolic labeling with [35S]methionine, 
lysates of MULT-1-3T3 cells were immunoprecipitated using anti–MULT-1 
mAb coupled to protein G–Sepharose. Before separation by 11.5% SDS-
PAGE, the samples were mock treated ( ) or digested with EndoH ( ). 
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MULT-1 (Fig. 3 B). The level of MULT-1 surface expres-
sion in 
 
 
 
m145
 
 mutant-infected cells was similar to that ob-
served upon infection with the 
 
 
 
6 and the 
 
 
 
6S1 mutants.
To assess whether the expression of MULT-1 is affected by
viral genes involved in regulation of two other NKG2D
ligands, the cells were infected with 
 
 
 
m152
 
 and 
 
 
 
m155
 
 vi-
ruses and stained for the expression of surface MULT-1 (Fig.
3 B). The fact that both mutants caused a complete loss of
membrane MULT-1 strongly argues against an additional
involvement of 
 
m152
 
 or 
 
m155
 
 in the regulation of MULT-1
expression. The formal evidence that m145 expression is the
crucial factor for down-modulation of surface MULT-1
came from the infection of cells with m145 revertant virus
(m145Rev), which caused a down-modulation of MULT-1
comparable to that observed upon infection with WT virus
(Fig. 3 B). Similar results were obtained on B12 and NIH/
3T3 cells (unpublished data). We concluded that the m145
gene is essential for abrogating the surface expression of
MULT-1. Led by the previously described capability of the
m152 gene to regulate surface disposition of both NKG2D
ligands and MHC class I molecules (19), we tested this possi-
bility for m145. However, cells infected with  m145 mutant
down-modulated MHC class I to the same extent as the cells
infected with WT virus (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041617/DC1). This
finding is in line with previously published results suggesting
that besides m04,  m06, and m152, there is no additional
MCMV gene affecting MHC class I surface expression (4).
To assess whether the m145 protein requires the cooper-
ation with other MCMV functions to down-modulate
MULT-1, we coinfected CV-1 cells with MULT-1-VV and
a recombinant vaccinia virus coding for the m145 protein
(m145-VV). Coinfection with MULT-1-VV and WT VV
served as a negative control. As shown in Fig. 3 C, the
membrane expression of MULT-1 was significantly im-
paired upon coinfection with m145-VV, whereas WT VV
had no effect. These results confirmed that m145 suffices for
MULT-1 down-regulation.
MCMV induces MULT-1 expression
Cells can react to infection or stress by up-regulating the ex-
pression of ligands for the activating NK cell receptors (10).
We tested the expression of MULT-1 mRNA in SVEC4-10
cells infected with WT or  m145 MCMV and found an
 10-fold induction of MULT-1 mRNA expression in
comparison with uninfected cells (Fig. 4 A). Similar results
were obtained on mouse embryonic fibroblasts (MEFs; un-
published data).
We tested whether the mRNA induction would also
lead to up-regulation of membrane-associated MULT-1. To
this end, SVEC4-10 cells (Fig. 4 B) or MEFs (not depicted)
were infected with WT or  m145 viruses and stained with
Figure 3. The m145 protein down-regulates MULT-1. (A and B) 
SVEC4-10 cells were infected with 1 PFU of GFP-positive viruses per cell or 
left uninfected. 12 h after infection, cells were collected and stained with 
anti–MULT-1 mAb. Cells incubated with the second antibody upon binding 
to irrelevant primary antibody were used as a negative control (dotted 
line). Each histogram represents 104 gated propidium iodide-negative, 
GFP-positive cells (infected) or GFP-negative (uninfected) cells. n.i., nonin-
fected cells. (C) CV-1 cells were infected with three MOI of WT VV, m145-VV, 
or MULT-1-VV or coinfected with MULT-1-VV/WT VV or MULT-1-VV/m145-VV 
per cell and, 14 h after infection, were analyzed for the expression of 
membrane-associated MULT-1 by staining with anti– MULT-1 mAb. Cells 
incubated with the second antibody in the absence of the primary anti-
body were used as a negative control (dotted line). Each histogram repre-
sents 104 gated propidium iodide-negative cells.JEM VOL. 201, January 17, 2005 215
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anti–MULT-1 mAb. Although WT infection of SVEC4-10
cells caused the down-modulation of surface MULT-1, in-
fection with  m145 virus resulted in an induction of sur-
face-expressed MULT-1, as compared with uninfected cells
(Fig. 4 B). Confocal analysis of SVEC4-10 cells confirmed
the flow cytometry data (Fig. 4 C). Although WT MCMV
infection caused a complete loss of surface MULT-1, the
protein was clearly induced on the surface of the cells in-
fected with the  m145 virus. In contrast with surface stain-
ing, intracellular MULT-1 expression was equally induced
in cells infected with WT and the  m145 virus (Fig. 4 C).
Similar results were obtained in MEFs (unpublished data).
Altogether, these results demonstrated that MCMV infection
induces the expression of the MULT-1 protein, but a viral
function prevents cell membrane expression.
Intracellular processing and transport of newly 
synthesized MULT-1
To study the effect of m145 on the fate of newly synthesized
MULT-1, CV-1 cells were coinfected with MULT-1-VV
and m145-VV. Coinfection of CV-1 cells with MULT-1-
VV and an unrelated VV recombinant was performed as a
negative control. Cells were metabolically labeled for 30
min, followed by chase periods of 1 and 6 h before immuno-
precipitation of MULT-1 proteins was performed. Before
separation on 10% SDS-PAGE, an aliquot of the precipitated
material was subjected to EndoH digestion to determine the
stage of maturation and intracellular transport of MULT-1.
As shown in Fig. 5, the bulk of newly synthesized MULT-1
protein remained in an EndoH-sensitive state during the
pulse period and 1 h of chase, suggesting a slow exit of
MULT-1 from the ER and cis-Golgi compartment. Within
6 h of chase, a majority of MULT-1 molecules acquired En-
doH resistance, indicative for the transit through the medial-
Golgi compartment. Extended chase periods determined a
half-life of MULT-1 of  16 h (unpublished data). Impor-
tantly, neither the glycosylation pattern, nor the rate of
intracellular transport to EndoH-resistant forms nor the half-
life of MULT-1 were affected by the m145 protein, even af-
ter 24 h of chase (unpublished data). Thus, the m145 glyco-
protein alters the intracellular distribution of MULT-1 and
its transport to the plasma membrane at a step after the pas-
sage through the ERGIC/cis-Golgi compartment. Because
coinfection of CV-1 cells with MULT-1-VV and m145-
VV resulted in an incomplete down-regulation of surface
MULT-1, escaping MULT-1 molecules might have influ-
enced the data obtained by immunoprecipitation. To ex-
clude this possibility, endogenous MULT-1 was immuno-
precipitated from MCMV-infected SVEC4-10 cells. The
slow maturation pattern of endogenous MULT-1 was in
agreement with the data obtained in MULT-1-VV–infected
cells (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20041617/DC1). Importantly, there was no influ-
ence of m145 expression on MULT-1 maturation and stabil-
ity in MCMV-infected cells. The presence of several differ-
ently glycosylated specific bands of endogenous MULT-1
might be a consequence of its slow exit from the ER/Golgi
compartment. The infection conditions in the experiment
allowed infection of the vast majority of cells ( 95%) as
confirmed by staining with anti-MCMV gp48 mAb in flow
Figure 4. MCMV infection stimulates MULT-1 expression. 
(A) SVEC4-10 cells were infected for 12 h with 1 PFU of the indicated 
GFP-expressing viruses per cell or were mock infected. Total RNA was iso-
lated from the cells, and the expression of MULT-1 mRNA was quantified 
by real-time RT-PCR. MULT-1 cDNA copies in each sample were normalized 
by measuring the  -actin cDNA copy numbers. Bars represent the ratio of 
MULT-1 and  -actin cDNA copy numbers in each sample. (B) SVEC4-10 
cells were infected with 1 PFU of the indicated GFP-expressing viruses per 
cell, or left untreated and, upon 12 h, harvested and stained with anti–
MULT-1 mAb. Histogram represents 104 gated propidium iodide–negative, 
GFP-positive (infected) or GFP-negative (uninfected) cells. (C) SVEC4-10 
cells were infected with 2 PFU/cell of the indicated GFP-expressing viruses 
and analyzed for the intracellular (bottom) or surface (top) expression of 
MULT-1. Infection was visualized by GFP expression.MULT-1 DOWN-REGULATION BY MCMV M145 PROTEIN | Krmpotic et al. 216
cytometry (unpublished data). Altogether, the results con-
firmed that m145 protein interferes with MULT-1 expres-
sion only beyond the ERGIC/cis-Golgi compartment.
m145 compromises virus control by NK cells in vivo
Provided that the data shown so far correctly reflect a major
function of m145, the  m145 mutant should be attenuated
in vivo in an NK-dependent fashion. To assess this, BALB/c
mice were infected with either WT MCMV, or  m145,
 m146,   m147/148 mutants or an m145 revertant virus
(Fig. 6, A and B). Note that each of these mutants is indistin-
guishable from WT MCMV with respect to virus growth in
fibroblasts (unpublished data). Half of the mouse groups
were treated with anti-asialo GM1 serum to determine the
contribution of NK cells to virus control in vivo. Virus titers
in organs were determined by plaque assay 4 d after infec-
tion. As seen in Fig. 6 (A and B), the infection with  m145
virus resulted in reduced virus titers as compared with WT
and the other mutants, but the attenuation of the  m145
mutant was found largely reversed after depletion of NK
cells. These data confirmed our assumption that m145 has a
relevant role in avoiding NK cell–mediated control of MCMV
in vivo. Reconstitution of the m145 gene (m145Rev) re-
sulted in virus resistance to NK cells and virus titers in tissues
comparable with those found after WT MCMV infection
(Fig. 6 B). More specific evidence for the involvement of
NKG2D receptor in NK cell–mediated control of  m145
mutant was obtained by injection of blocking anti-NKG2D
mAb into the groups of infected mice. Similar to depletion
of NK cells by cytolytic antibodies, injection of blocking
anti-NKG2D mAb that does not affect the size of NK cell
populations (unpublished data) led to a significant increase of
 m145 virus titers (Fig. 6 C), whereas the titer of m145 re-
vertant virus was not affected. These data strongly support
the interpretation that the interaction of MULT-1 with
NKG2D is responsible for the NK cell–mediated control of
 m145 mutant virus. The  m145 virus is also attenuated in
BXD-8/Ty mice that possess the natural killer gene complex
(NKC) from C57BL/6 mouse strain, but are susceptible to
MCMV infection due to the mutation of Ly49h gene (refer-
ences 26, 27 and Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20041617/DC1), pointing to a general
role of m145-mediated inhibition of NK cell activity.
Figure 5. The m145 does not affect ER export of the MULT-1 protein. 
CV-1 cells were infected with control-VV or coinfected with MULT-1-VV 
and control VV or with MULT-1-VV and m145-VV and analyzed 12 h after 
infection. The cells were metabolically labeled for 30 min and chased for 
the indicated times, and the lysates were immunoprecipitated using anti-HA 
antibodies coupled to protein A–Sepharose. Before separation by 10% 
SDS-PAGE, the samples were mock treated ( ) or digested by EndoH ( ). 
R, EndoH resistant; S, EndoH sensitive; D, EndoH digested.
Figure 6.  m145 virus is attenuated in vivo in an NK-dependent 
fashion. (A and B) NK cell–depleted or undepleted BALB/c mice were 
injected i.v. with 2   105 PFU of indicated viruses. The mice were killed 4 d 
after infection, and viral titers in organs were determined. Titers in the 
spleen of individual mice (circles) and median values (horizontal bars) are 
shown. (C) BALB/c mice were injected i.p. with blocking anti-NKG2D mAb 
or left untreated. 4 d after i.v. infection with 2   105 PFU of indicated 
viruses, the mice were killed and viral titers in organs were determined. 
Titers in the spleen and lungs of individual mice (circles) and median 
values (horizontal bars) are shown.JEM VOL. 201, January 17, 2005 217
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DISCUSSION
In this work, we describe the effects of MCMV infection on
the expression of MULT-1, a recently described NKG2D
ligand (14, 15). Despite the fact that MCMV infection
strongly induces MULT-1 expression, the MULT-1 glyco-
protein is down-regulated by an MCMV function from the
surface of infected cells. The viral protein responsible for the
down-modulation of MULT-1 is encoded by the m145 gene.
In contrast with cells infected with WT MCMV, the  m145-
infected cells retain and even up-regulate MULT-1 on their
plasma membrane. Consequently, the virus mutant lacking the
m145 gene displays NK cell–dependent attenuation in vivo.
NKG2D ligands show either a constitutively low level or
a complete lack of expression in normal tissues (13, 28). A
tight regulation of cellular ligands for activating NK cell re-
ceptors may be essential for the prevention of autoaggressive
NK cell activities. Inducibility by infection, as shown here
for the MULT-1, points to their strong systemic role. To
limit pathogen multiplication and dissemination at early
stages of infection before activation of adaptive immunity,
the host might alarm NK cells by up-regulating these ligands
on the surface of infected cells.
Apparently, MCMV cannot avoid the induction of
MULT-1 transcription in infected cells. However, to avoid the
consequences of MULT-1 transcription, MCMV has devel-
oped a gene that encodes a protein that modulates the function
of MULT-1. Rather than silencing the NKG2D receptor,
evolution selected MCMV to control the signaling through
the different ligands of NKG2D. This is why the MCMV ge-
nome harbors three individual genes to modulate the three
known ligands of murine NKG2D. This evolutionary solution
is probably very specific for large DNA viruses because only
these viruses provide the genomic space to encompass multiple
genes and gene families that seem to be selectively devoted to
different aspects of virus host interaction because their absence
has no effect on viral morphogenesis in cell culture.
Remarkably, the NK cell regulators of MCMV are com-
prised in the m145 gene family (Fig. 1 A) encoding glyco-
proteins that share some structural similarities with MHC
class I proteins (7). Two other MCMV genes are involved in
the control of NKG2D ligands: m152, responsible for the
down-modulation of RAE-1 (19, 20), and m155, whose
protein product regulates surface expression of H60 (22, 23).
Another member of this gene family interferes with the
function of NK cells. The m157 protein is a ligand for the
activating NK cell receptor Ly49H, responsible for the resis-
tance of Cmv1r mouse strains to MCMV (7, 8). Deletion of
the m157 gene results in higher virulence of the virus mutant
in vivo (9). Under selective in vivo pressure of Ly49H,
MCMV tends to inactivate the m157 gene by mutation (29,
30). In addition, MCMV homologue for MHC class I en-
coded by m144 gene inhibits NK function by serving as a
ligand for an inhibitory NK cell receptor although the puta-
tive receptor remains elusive (31).
The molecular mechanisms by which the NKG2D ligand
regulators act are not yet clear. The first regulator found, the
gp40 encoded by m152, was identified by us as a modulator
of MHC class I expression (21). Unlike certain MHC class I
regulators of HCMV (32), the MCMV m152/gp40 does not
act by retrograde translocation of the protein target from the
ER into the cytosol and subsequent degradation by the cyto-
solic proteasome. Instead, the MHC class I protein binds an-
tigenic peptides and matures to the stage of EndoH resistant
glycoprotein modification, showing that the protein does not
exit the ER in a retrograde fashion. Furthermore, the half-life
of the target protein is not affected (21, 33). Thus, the m152
misdirects the MHC class I molecule into a compartment
with ERGIC/cis-Golgi properties. Further studies are re-
quired to understand whether NKG2D ligands affected by
m152 and other MCMV regulators follow similar patterns.
According to our understanding, the species-specific her-
pesviruses have coevolved with their hosts. Therefore, the
presence of multiple NKG2D ligands and ligand modulators
may simply reflect mutations and duplications of host defense
principles and the necessary reciprocal viral counterstrategies.
Alternatively, different ligands may have in fact diverse roles
in different tissues due to tissue-specific ligand expression pat-
terns. Because research on MCMV is based on only two iso-
lates, Smith and K181, which, in fact, for unknown reasons
differ in virulence, it is unknown whether wild-type strains of
MCMV differ with respect to number and function of
NKG2D ligand modulators that might affect virus distribu-
tion patterns in tissues. The fact that MULT-1 has a stronger
affinity for NKG2D binding than that of RAE-1 and H60
(15), points to the relevance of MULT-1/NKG2D signaling
as a target for the virus. Avoiding MULT-1/NKG2D signal-
ing may be one of the first host checkpoints to be bypassed in
the process of establishing MCMV infection.
NKG2D is an important costimulatory receptor for
CD8  T cells (18). The evasion function should also affect
the triggering of virus-specific CTLs. Therefore, a virus
lacking one or several NKG2D evasion genes should be
more prone to activate CTLs. Thus, viral immunoevasins in-
volved in the control of NKG2D ligands may not only con-
tribute to the control of acute infection but also to viral im-
mune surveillance during conditions of latent infection and
reactivation episodes.
The results obtained in the MCMV system can be used
to extrapolate the significance of HCMV-mediated down-
regulation of NKG2D ligands. It has been shown that
HCMV-encoded UL16 protein prevents membrane expres-
sion of ULBP1 and 2 as well as MICB and reduces sensitivity
of infected cells to NK cell lysis (34–36). Although the pre-
cise mechanism by which UL16 down-regulates NKG2D
ligands is still unknown, it seems that UL16 forms stable
complexes with MICB in ER/cis-Golgi compartment of in-
fected cells, thus preventing membrane expression of this
NKG2D ligand (37, 38). Because, together with this paper,
already three MCMV genes have been identified that inter-
fere with the expression of NKG2D ligands, it is likely that
HCMV also encodes additional, yet unidentified proteins
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MATERIALS AND METHODS
Cells. SVEC4-10 (endothelial cells derived from C3H/HeJ mouse strain,
CRL-2181; American Type Culture Collection), CV-1 (fibroblasts derived
from the kidney of a male adult African green monkey, CCL-70; American
Type Culture Collection), B12 (subclone of an immortalized line of BALB/
c fibroblast; reference 19), BALB/3T3 (fibroblasts derived from BALB/c
mouse strain, CCL-163; American Type Culture Collection), and NIH/
3T3 (fibroblasts derived from NIH Swiss mouse, CRL-1658; American
Type Culture Collection) cells were cultivated in DMEM supplemented
with 10% FCS. MEFs prepared from BALB/c mice were cultivated in
MEM supplemented with 3% FCS or alternatively in DMEM supple-
mented with 10% FCS.
To obtain cell transfectants, the HA-tagged MULT-1 ORF was cloned
from a p7.5K131-based plasmid (39) into the SalI restriction site of pB45-
Neo, provided by E.R. Podack (University of Miami School of Medicine,
Miami, FL; reference 40). The plasmid was transfected into NIH/3T3 fi-
broblasts using SuperFect Transfection Reagent (QIAGEN), according to
the manufacturer’s instructions. MULT-1–transfected 3T3 cells (MULT-1-
3T3) were selected and cultured in DMEM supplemented with 10% FCS
and 500  g/ml G418 (GIBCO-BRL).
Production of anti–MULT-1 mAb 1D6. MULT-1 protein was gener-
ated by cloning the sequence of the extracellular domain (cDNA provided
by W.M. Yokoyama, Washington University School of Medicine, St.
Louis, MO) into a bacterial expression vector (pET3a; Novagen). Protein
was expressed in inclusion bodies in BL21(DE3), subsequently purified, and
in vitro refolded under identical conditions as described for the generation
of soluble NKG2D (41).
DA rats were primed and boosted in 2-wk interval by intradermal in-
jections of 50  g MULT-1 protein diluted in PBS with addition of Fre-
und’s adjuvant (Sigma-Aldrich). Serum was screened after each injection by
ELISA. 3 d preceding the fusion, animals were boosted i.p. with 50  g
MULT-1 protein diluted in PBS. Splenocytes from the boosted rats were
fused with Sp2/0 murine myeloma cells. The hybridomas were selected by
growing in RPMI 1640 medium (GIBCO-BRL) supplemented with HAT
medium (GIBCO-BRL) and 10% FCS. Supernatants of hybridomas were
collected and screened against the MULT-1 protein by ELISA. Positive hy-
bridomas were tested in FACS on SVEC4-10 cell line. The hybridomas
positive in both assays were subcloned to clone density, and supernatants
were collected.
Viruses. The BAC-derived strain MCMV-GFP (25), here referred to as
WT virus, is a derivative of the MCMV strain MW97.01 (42), which has
previously been shown as biologically equivalent to the MCMV Smith
strain (VR-194 recently reaccessed as VR-1399; American Type Culture
Collection). To generate the deletion mutants listed in Table I, a PCR-
based mutagenesis procedure was applied as described previously (43). In
brief, a kanamycin resistance gene (kanR) was PCR amplified using primers
containing 20–22 nucleotides (nt) at their 3 -ends specific for kanR and 50–
60 nt at their 5 -ends homologous to the target region in the BAC-cloned
genome. The PCR fragments were integrated into the BAC, thereby re-
placing the respective target gene. To construct a rescuant of the mutant
strain MCMV-GFP m145, the kanR cassette in the respective BAC was
excised by FLP-mediated recombination as described previously (4), result-
ing in BAC pSM3fr m145-K. A 4.7 kbp KpnI fragment (nt 203952–
208669 of the MCMV genome [24] was subcloned into the shuttle vector
pST76KSR). Using the resulting shuttle plasmid, the DNA sequence with
the m145 gene was reintroduced into the BAC pSM3fr m145-K by a two-
step replacement procedure as described previously (42). Recombinant
MCMV BACs were characterized by restriction analysis and viruses were
reconstituted by transfection of the MCMV-BACs into MEFs as described
previously (4). For preparation of virus stocks, MCMV recombinants were
propagated on MEFs and purified. Titers of virus stocks were determined
by standard plaque assay on MEFs. Tissue culture-grown virus preparations
were used for mouse inoculations.
Production of recombinant vaccinia viruses. For the generation of a
recombinant vaccinia virus, the MULT-1 cDNA sequence (NCBI acces-
sion no. AK020784) was PCR amplified from pmX-IgMULT7 plasmid
(obtained by courtesy of W.M. Yokoyama). Using forward primer 5 -CGC-
CCAAGCTTGGGATGGAGCTGACTGCCAGT3` and reverse primer
5 -CGAGGTACCCGCGGGTCGACCCGTCACGCGTAATCTGGAA-
CATCGTATGGGTATGGGATCCCATCAAT-3  the hemagglutinin
(HA) epitope sequence was added COOH terminally. m145  DNA was
PCR amplified from DNA of the MCMV Smith strain and COOH termi-
nally flag-tagged using primers for 5 -CGAAGATCTTCCATGGAC-
CGTCGGGTGGTC-3  and rev 5 -CGGAATTCCTCACTTGTCGTC-
GTCGTCCTTGTAGTCCGCCTCTATCGTCTT-3 . The PCR products
were cloned into 5 -HindIII and 3 -KpnI (MULT-1) or 5 -BglII and 3 -
EcoRI (m145) restriction sites of plasmid p7.5K131 (39). The constructs
were used for generation of recombinant vaccinia viruses expressing
MULT-1 (MULT-1-VV) or m145 (m145-VV) by homologous recombi-
nation with the vaccinia strain Copenhagen. Vaccinia recombinants were
selected by infection of 143 tk  cells in the presence of 100  g/ml bro-
modeoxyuridine as described previously (44). As a VV control virus an
ICP47 expression vaccinia recombinant was used (45).
Metabolic labeling of cells and immunoprecipitation. Subconfluent
layers of cells were labeled with [35S]methionine (Amersham Biosciences) at
a concentration of 500  Ci/ml at 37 C for 30 min and chased in the pres-
ence of 10 mM of nonlabeled methionine. After being washed with ice-
cold PBS, cells were lysed in 1 ml of lysis buffer (140 mM NaCl, 5 mM
MgCl2, 20 mM Tris, pH 7.6, 1 mM PMSF, 0.5 mM leupeptin, 1  M pep-
statin A), containing 1% (vol/vol) IGEPAL (Sigma-Aldrich) for 20 min and
centrifuged at 13,000 g for 30 min.
The lysates were incubated for 1 h at 4 C with 0.5  g of anti-HA
(Sigma-Aldrich). Immunoprecipitation was performed as described previ-
ously (46, 47). In brief, immune complexes were retrieved with protein
A-Sepharose (Amersham Biosciences) (60  l of 1:1 buffer-Sepharose slurry,
for 1 h at 4 C). The Sepharose beads were washed three times with (0.2%
[vol/vol] IGEPAL, 10 mM Tris-HCl, pH 7.6, 140 mM NaCl, 2 mM
EDTA), twice with (0.2% [vol/vol] IGEPAL, 10 mM Tris-HCl, pH 7.6,
500 mM NaCl, 2 mM EDTA), and once with (10 mM Tris-HCl, pH 7.6)
washing buffers. The immune complexes bound to Sepharose beads were
resuspended in 50 mM phosphate buffer, pH 5.5, containing 0.02% (wt/
vol) SDS, 0.1% (vol/vol) IGEPAL, 0.2 mM PMSF, and 0.1 M 2-mercapto-
ethanol. Sepharose-bound immune complexes were mock treated or incu-
bated with 2 mU of Endoglycosidase H (EndoH; Roche Diagnostics) at
Table I. MCMV mutants
Deletion
Mutants Rangea ORFs
MCMV-GFP – –
MCMV-GFP 6 203,002–217,799 m144–m158
MCMV-GFP 6S1 202,746–207,298 m144–m148
MCMV-GFP 6S2 207,354–212,803 m149–m153
MCMV-GFP 6S3 212,946–216,883 m154–m157
MCMV-GFP m144 202,746–203,892 m144
MCMV-GFP m145 204,032–205,492 m145
MCMV-GFP m146 205,646-206,774 m146
MCMV-GFP m147/m148 206,866–207,265 m147, m148
MCMV-GFPm145Revb ––
aNucleotide positions refer to reference 24.
bThe genome of MCMV-GFPm145Rev was constructed by reinsertion of the m145 
gene into the genome of MCMV-GFP m145.JEM VOL. 201, January 17, 2005 219
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37 C overnight. Digestion was stopped by addition of sample buffer and
heating at 94 C for 5 min. The precipitates were analyzed by 10% SDS-
PAGE. Dried gels were exposed to Kodak BioMaxMR films for 1–3 d.
Quantification of MULT-1 mRNA by real-time RT-PCR. SVEC4-
10 and MEF cells (2   106) were mock-infected or infected with WT or
 m145 MCMV (1 and 0.5 PFU/cell, respectively). Upon 12 h of infection,
the cells were collected and total RNA was isolated by TriPure reagent
(Roche Diagnostics) according to the manufacturer’s instruction. cDNA was
synthetized from 1  g of total RNA by using the 1st Strand cDNA Synthesis
Kit for RT-PCR (Roche Diagnostics, containing: oligo (dT)15 primers (0.04 U
A260), 1 mM dNTPs, 5 mM MgCl2, 2.5 U/ l RNase inhibitor, AMV RT
buffer ( 1), and 1 U/ l AMV reverse transcriptase; final volume of reaction,
20  l) under the following conditions: 10 min at 25 C, 1 h at 42 C, 10 min
at 95 C, and 10 min at 4 C. The cDNA was diluted 1:5 in water and 2  l
was used for each quantitative real-time PCR reaction designed to measure
the number of MULT-1 and  -actin cDNA copies in each sample and per-
formed on LightCycler (Roche Diagnostics). The MULT-1 cDNA PCR
product (185 bp) was amplified by using exon spanning MULT-F (5 -CTC-
ATAGGAACAGCATGA-3 ) and MULT-R (5 -TCCTGTGAAAT-
GTTTGTC-3 ) primers and LightCycler-FastStart DNA Master SYBER
green I Kit (Roche Diagnostics) according to manufacturer’s instructions. In-
corporation of Syber green I dye into the PCR products was automatically
measured by the LightCycler after each of 45 cycles of amplification (0 s at
95 C, 10 s at 54 C, and 8 s at 72 C). The very same conditions and following
primers: 5 -TTCTACAATGAGCTGCGT-3  ( ACT-LCF) and 5 -ATC-
ACAATGCCTGTGGTA-3  ( ACT-LCR), spanning exons 2 and 3, were
used to amplify the mouse  -actin cDNA PCR product (191 bp). Serial dilu-
tions with known copy numbers (106, 105, 104, 103, 102, 101 in 2  L) of plas-
mid pB45-Neo containing a complete cDNA sequence of MULT-1 were
used to obtain a standard amplification curve (error   0.0406, r    1.00) to
quantify MULT-1 and  -Actin cDNA copy numbers in each sample. The
quantification was done automatically by LightCycler Software V3 and Sec-
ond Derivative Maximum method.
Confocal microscopy. SVEC4-10 cells were grown on glass coverslips
and infected with 1 PFU of WT or  m145 MCMV per cell or mock in-
fected. Upon 12 h of infection, the cells were washed in PBS, fixed with
2.5% (wt/vol) paraformaldehyde in PBS for 20 min, and immunostained.
Unspecific binding of antibodies was blocked with 0.2% (wt/vol) fish skin
gelatin. The staining was performed with anti–MULT-1 mAb in combina-
tion with goat anti–rat PE. Infected cells were visualized by GFP expression.
Flow cytometry. SVEC4-10, MULT-1-3T3, NIH/3T3, BALB/3T3,
and B12 cells were mock treated or infected with MCMV (1–2 PFU/cell)
and trypsinized 12 h after infection. CV-1 cells were mock treated or in-
fected with VV (3 multiplicity of infection [MOI]/cell) and harvested 14 h
after infection. Cells were washed in PBS supplemented with 1% BSA and
0.1% NaN3 and stained with either PE-NKG2D tetramer (19), rat anti-H60
mAb clone 205303, provided by J.P. Houchins (R&D Systems, Minneapo-
lis, MN), rat anti–RAE-1 , ,  mAb CX1, provided by L.L. Lanier (Uni-
versity of California, San Francisco, CA; reference 20), or rat anti–MULT-1
mAb. After washing, bound antibodies were visualized by the addition of
PE-labeled goat anti–rat IgG (Caltag Laboratories). Cells incubated with
PE-streptavidin served as negative control for cells stained with PE-
NKG2D tetramer, whereas cells incubated with the second antibody served
as negative control for cells stained with anti-H60 and anti–RAE-1 ,  ,  
mAb. Cells stained with irrelevant rat mAb followed by PE-labeled goat
anti–rat IgG were control for cells stained with anti–MULT-1 mAb. After
staining, cells were analyzed with a Becton Dickinson FACScan and gated
with propidium iodide-negative cells.
Animals, infection conditions, and detection of infectious MCMV
in tissues. BALB/c (H-2d) and BXD-8/Ty (H-2b; The Jackson Labora-
tory) mice were housed and bred under specific pathogen-free conditions at
the Central Animal Facility of the Medical Faculty, University of Rijeka, in
accordance with the guidelines contained in the International Guiding Prin-
ciples for Biomedical Research Involving Animals. The Ethical Committee
at the University of Rijeka approved all animal experiments described here.
6–8-wk-old female mice were used in experiments.
Mice were injected i.v. with 2   105 PFU (BALB/c) or 4   105 PFU
(BXD-8/Ty) of WT MCMV or recombinant viruses in a volume of 500  l
of diluents. Organs were collected 4 d after infection and viral titers were
determined by a standard viral plaque-forming assay performed on MEFs.
Depletion of NK cell subsets in vivo. The depletion of NK cells was
performed by i.p. injection of rabbit antibodies to asialo GM-1 (Wako
Chemicals) at the dose of 25  l, 6 h before infection. The efficacy of deple-
tion was assessed by cytofluorometric analysis of spleen cells using biotin-
labeled anti–mouse pan-NK cells mAb DX5 (BD Biosciences). The NKG2D
was blocked by i.p. injection of blocking anti-NKG2D mAb (R&D Sys-
tems) at the dose of 100  g/mouse, 12 h before infection.
Online supplemental material. Lack of influence of m145 gene on
MHC class I expression is depicted in Fig. S1. The finding that MCMV in-
fection does not alter maturation pattern of MULT-1 molecule before its
passing through ERGIC/cis-Golgi compartment is shown in Fig. S2. In
Fig. S3, the attenuation of  m145 virus in BXD-8/Ty mice is presented.
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20041617/DC1.
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